In Vitro Mutagenesis

Abstract

In vitro mutagenesis allows a nucleic acid sequence (and hence an encoded protein sequence) to be altered either randomly or in a predefined way. Its principal applications are the investigation of nucleic acid or protein structure/function, the investigation of cellular pathways (for example, biochemical or signaling) and gene therapy.

Keywords: mutagenesis; site‐directed; random; oligonucleotide; engineering

Figure 1.

Schematic diagram showing the stages involved in random mutagenesis of cloned DNA. Various permutations are possible. For example, the starting DNA may be a cloned fragment (as illustrated) or a PCR amplification product that is mutated and then cloned.

Figure 2.

Site‐directed mutagenesis employing a mutagenic oligonucleotide. The mutagenic oligonucleotide has sufficient sequence complementarity to hybridize to the target template DNA, but contains a predefined sequence change (*). Following chain extension and ligation, a heteroduplex results comprising one mutant strand and one wild‐type strand. When transformed into bacteria, replication produces homoduplexes of either mutant or wild‐type plasmid and colonies are screened for those in which the mutant plasmid has prevailed. dNTPs: deoxynucleoside triphosphates.

Figure 3.

Approaches for site‐directed mutagenesis using the PCR. (a) Substrate DNA is amplified using the PCR in which one primer contains a predefined sequence change (*). Both strands of the final PCR product contain the mutation: the mutagenic primer (primer B in this illustration) introduces the mutation into one strand and this directs its replication into the complementary strand. In this approach, the location of the mutation is limited by the position of the mutant primer. (b) One approach by which the PCR can be used to introduce a mutation anywhere within a DNA fragment. Primers A and D define the extent of the final mutated fragment. Primers B and C contain the desired sequence change and are complementary. The substrate DNA is amplified with primers A and B in one reaction and primers C and D in a second reaction. The resulting PCR products each contain the mutation in both of their strands. When used in combination in a further PCR containing only primers A and D, cross‐hybridization is possible between A–B and C–D strands and the PCR polymerase fills in to yield a full‐length A–D fragment that contains the desired mutation in both strands. The relative positions of primers A, B, C and D permit a mutation to be introduced anywhere within a DNA fragment. Several variations on this theme are possible.

Figure 4.

Chimeric RNA/DNA oligonucleotides used for directing predefined point mutations into the genome via DNA mismatch repair. (a) Schematic diagram showing the following features of the chimeric oligonucleotides: regions of RNA (dotted lines), regions of DNA (full lines), hairpin loops and the position of the point mutation (*) specified by the chimera. The oligonucleotides form a double‐stranded nucleic acid in which the two strands are either complimentary (vertical bars) at all positions except the mutation site or joined by hairpin loops. At the mutation site, the DNA sequence flanked by stretches of RNA contains mutant sequence and the sequence of the complementary strand is wild type. The RNA is believed to function more efficiently during homologous pairing in the nucleus than would DNA. The ribonucleotide precursors used in the synthesis of the RNA stretches are chemically modified to protect against RNases within the cell. This, together with the double‐stranded circular structure (the hairpin loops eliminate DNase‐sensitive free ends), increases the intracellular survival of the oligonucleotide. (b) An example of a chimeric oligonucleotide containing the features described in (a). Upper case letters represent DNA, lower case letters represent RNA, the targeted point mutation is underlined (A in the wild‐type sequence is to be replaced by T).

Figure 5.

Approaches for deletion mutagenesis. (a) An exonuclease is used to partially delete a starting fragment of DNA. When cloned, the resulting bacterial colonies comprise a library of deletion fragments of different lengths. This is due to the nucleolytic activity extending further for some molecules of the starting DNA than others during the exonuclease reaction. Depending on the exonuclease used, deletions may be introduced at the 5′ or 3′ end of the starting DNA. (b) The PCR can be used to delete a starting fragment of DNA from either or both ends, or to introduce an internal deletion. For both approaches, the extent of the deletion can be specified with absolute precision, unlike deletions introduced using an exonuclease. PCR products containing deletions can either be used directly or cloned (for example, for expression).

close

References

Bowen DJ, Standen GR, Granville S, et al. (1997) Genetic diagnosis of factor V Leiden using heteroduplex technology. Thrombosis and Haemostasis 77(1): 119–122.

Cole‐Strauss A, Yoon K, Xiang Y, et al. (1996) Correction of the mutation responsible for sickle cell anemia by an RNA–DNA oligonucleotide. Science 273(5280): 1386–1389.

Hazard AL and Senior AE (1994) Mutagenesis of subunit delta from Escherichia coli F1F0‐ATP synthase. Journal of Biological Chemistry 269(1): 418–426.

Hill F, Felix IR, McDougall MG, et al. (1999) Random mutagenesis using 2‐amino‐9‐(2‐deoxy‐beta‐D‐ribofuranosyl)purine‐5′‐triphosphate and the polymerase chain reaction. Nucleosides and Nucleotides 18(11–12): 2677–2684.

Kren BT, Bandyopadhyay P and Steer CJ (1998) In vivo site‐directed mutagenesis of the factor IX gene by chimeric RND/DNA oligonucleotides. Nature Medicine 4(3): 285–290.

Lerner CG, Kobayashi T and Inouye M (1990) Isolation of subtilisin prosequence mutations that affect formation of active protease by localized random polymerase chain reaction mutagenesis. Journal of Biological Chemistry 265(33): 20085–20086.

Liao X and Wise JA (1990) A simple high‐efficiency method for random mutagenesis of cloned genes using forced nucleotide misincorporation. Gene 88(1): 107–111.

Little JB (2000) Radiation carcinogenesis. Carcinogenesis 21(3): 397–404.

Park H, Sung Sup Park, Eun Hee Jin, et al. (1998) Identification of functionally important residues of human thrombopoietin. Journal of Biological Chemistry 273(1): 256–261.

Vipond IB and Halford SE (1996) Random mutagenesis targeted to the active site of the Eco RV restriction endonuclease. Biochemistry 35(6): 1701–1711.

Further Reading

Abuzura P and Marians KJ (1984) Enzymatic techniques for the isolation of random single‐base substitutions in vitro at high frequency. Proceedings of the National Academy of Sciences of the United States of America 81(71): 2030–2034.

Ausubel FM, Brent R, Kingston RE, et al. (1999) Short Protocols in Molecular Biology. New York: John Wiley.

Gamper HB Jr, Cole‐Strauss A, Metz R, et al. (2000) A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry 39(19): 5808–5816.

Glover DM and Hames D (eds.) (1995) DNA Cloning I, A Practical Approach. Oxford, UK: IRL Press.

Lehmann M and Wyss M (2001) Engineering proteins for thermostability: the use of sequence alignments versus rational design and directed evolution. Current Opinion in Biotechnology 12(4): 371–375.

Myers RM, Lerman LS and Maniatis T (1985) A general method for saturation mutagenesis of cloned DNA. Science 229(4710): 242–247.

Peracchi A (2001) Enzyme catalysis: removing chemically ‘essential’ residues by site‐directed mutagenesis. Trends in Biochemical Sciences 26(8): 497–503.

Russell CS and Clarke LA (1999) Recombinant proteins for genetic disease. Clinical Genetics 55(6): 389–394.

Storici F, Lewis LK and Resnick MA (2001) In vivo site‐directed mutagenesis using oligonucleotides. Nature Biotechnology 19(8): 773–776.

Watson JD, Gilman M, Witkowski J and Zoller M (eds.) (1992) Recombinant DNA. New York: Scientific American Books.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Bowen, Derrick John(Jan 2006) In Vitro Mutagenesis. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0005677]